OMass Therapeutics, an Oxford-based developer targeting genetic adrenal disorders, raised $310 million in a private financing. The company said it plans to pursue programs in endocrinology, taking aim at competitive ground shaped by acquisitions and blockbuster momentum from peers such as Neurocrine and Vertex. The scale of the round signals renewed investor confidence in endocrine genetics as a tractable therapeutic area—particularly where mechanism-based targeting can translate into differentiated clinical development paths. Attention will now turn to how OMass deploys capital across discovery, preclinical validation, and early clinical execution. For the sector, the financing also highlights a pattern: large late-stage private capital is being used to establish platform advantages and accelerate time-to-clinic in genetically defined endocrine populations.